Replies to post #457603 on Anavex Life Sciences Corp (AVXL)

[Hosai]

But we already know it was significant...the Sept 2023 PR from Anavex (overseen by Dr Jin who has 25 years with FDA as a lead on AD trials) had ADAS COG with a p value of 0.026 i.e 2.26 in a 100 chance that the improvement was due to chance. The FDA draft guidance now states this is the end point they care most about now, not ADL as it's too difficult to show in early AD studies (though Missling did say ADL was trending in right direction in latest call).

[Steady_T]

Different diseases with different disease pathways. Not an apples to apples comparison.

If the Results for Rett weren't significant ao why would they be for Alz